A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy
AbstractSignificant advances in the understanding of the pathophysiology of pulmonary arterial hypertension over the past two decades have led to the development of targeted therapies and improved patient outcomes. Currently, a broad armamentarium of pulmonary arterial hypertension-specific drugs exists to assist in the treatment of this complex disease state. In this manuscript, we provide a comprehensive review of the current Food and Drug Administration (FDA)-approved pulmonary arterial hypertension-specific therapies, and their supporting evidence for adults, targeting the nitric oxide, soluble guanylate cyclase, endothelin, and prostacyclin pathways. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Ataya, A.; Cope, J.; Alnuaimat, H. A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. J. Clin. Med. 2016, 5, 114.
Ataya A, Cope J, Alnuaimat H. A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. Journal of Clinical Medicine. 2016; 5(12):114.Chicago/Turabian Style
Ataya, Ali; Cope, Jessica; Alnuaimat, Hassan. 2016. "A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy." J. Clin. Med. 5, no. 12: 114.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.